RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07837739, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed primary non-small cell lung cancer, pathologic stage IA2 to IIB; protocol summary further specifies lung adenocarcinoma / predominantly non-squamous histology.

    Inclusion criterion 2

    EGFR mutation-positive disease confirmed by the central laboratory, including exon 19 deletion, L858R, exon 20 insertion, or PACC mutation.

    Inclusion criterion 4

  3. For stage IA2 disease, at least one protocol-defined high-risk feature: invasive component >2 cm; lymphovascular invasion; high-grade pattern comprising ≥20% solid, micropapillary, cribriform, or complex glandular components; spread through air spaces (STAS); or sublobar resection (segmentectomy/wedge resection).

    Inclusion criterion 3

  4. ECOG Performance Status 0-1.

    Inclusion criterion 7

  5. Hematologic criteria: RBC ≥3.0×10\^12/L; WBC ≥3.5×10\^9/L; ANC ≥1.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin ≥90 g/L.

    Inclusion criterion 8

    Renal function: serum creatinine ≤1.2×ULN.

    Inclusion criterion 9

    Hepatic function: total bilirubin ≤1.5×ULN; ALT and AST ≤1.5×ULN.

    Inclusion criterion 10

  6. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study.

    Inclusion criterion 13

    Pregnancy or breastfeeding.

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07837739, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18-75 years, male or female, with written informed consent.
  • Histologically confirmed primary non-small cell lung cancer, pathologic stage IA2 to IIB; protocol summary further specifies lung adenocarcinoma / predominantly non-squamous histology.
  • For stage IA2 disease, at least one protocol-defined high-risk feature: invasive component >2 cm; lymphovascular invasion; high-grade pattern comprising ≥20% solid, micropapillary, cribriform, or complex glandular components; spread through air spaces (STAS); or sublobar resection (segmentectomy/wedge resection).
  • EGFR mutation-positive disease confirmed by the central laboratory, including exon 19 deletion, L858R, exon 20 insertion, or PACC mutation.
  • Complete surgical resection with negative margins (R0); lobectomy or sublobar resection may be included according to the protocol.
  • No previous antitumor treatment, including no neoadjuvant radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
  • ECOG Performance Status 0-1.
  • Hematologic criteria: RBC ≥3.0×10\^12/L; WBC ≥3.5×10\^9/L; ANC ≥1.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin ≥90 g/L.
  • Renal function: serum creatinine ≤1.2×ULN.
  • Hepatic function: total bilirubin ≤1.5×ULN; ALT and AST ≤1.5×ULN.
  • Able and willing to comply with protocol-specified treatment/observation and follow-up.
  • Adequate tumor tissue available and willingness to provide tissue and blood samples for study analyses.
  • Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study.

Exclusion Criteria:

  • Contraindication to anesthesia or surgery, or death attributable to the surgical procedure before study enrollment/evaluation.
  • Any systemic disease incompatible with participation in the clinical study or inability to provide written informed consent.
  • Pregnancy or breastfeeding.
  • Known active alcohol or drug abuse or dependence.
  • Any serious or unstable medical condition or psychiatric disorder that, in the investigator's judgment, would make participation inappropriate.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Quoted from ClinicalTrials.gov, NCT07837739, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07837739, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07837739